M344: Potent HDAC Inhibitor with IC50 100 nM for Precision Cancer and HIV Latency Research

Executive Summary: M344 is a cell-permeable histone deacetylase inhibitor (HDACi) with an IC50 of 100 nM, demonstrating submicromolar activity in multiple cancer cell lines and viral latency models (Brumfield et al. 2025). Its mechanism involves HDAC inhibition, leading to increased histone acetylation and altered gene expression. M344 induces cell cycle arrest and apoptosis in neuroblastoma, breast cancer, and medulloblastoma cells under defined conditions. The compound enhances radiation sensitivity and modulates NF-κB signaling, showing promise in HIV-1 latency reversal. Supplied by APExBIO, M344 is validated for both in vitro and ex vivo workflows with precise solubility and storage guidelines (APExBIO M344).

Biological Rationale

Histone deacetylase (HDAC) enzymes remove acetyl groups from lysine residues on histone tails, resulting in chromatin condensation and reduced gene transcription. Dysregulated HDAC activity is associated with oncogenesis, resistance to apoptosis, and impaired cell differentiation (Brumfield et al. 2025). HDAC inhibitors such as M344 target these enzymes to restore gene expression patterns critical for tumor suppression and immune modulation. In pediatric neuroblastoma, HDAC overexpression correlates with tumor progression and poor prognosis (Brumfield et al. 2025).

Mechanism of Action of M344

M344 inhibits HDAC enzymes with a half-maximal inhibitory concentration (IC50) of 100 nM, measured in cell-free biochemical assays (APExBIO M344). Inhibition of HDAC activity increases acetylation of histone H3 and H4 tails, relaxing chromatin structure and enabling transcription of genes involved in cell cycle regulation, differentiation, apoptosis, and immune response. In cancer models, M344 treatment triggers G0/G1 cell cycle arrest and activates caspase-mediated apoptosis, as observed in neuroblastoma and breast cancer cell lines (Brumfield et al. 2025). M344 also regulates the NF-κB transcription factor, enhancing latent HIV-1 LTR gene expression, which positions it as an anti-latency agent in HIV research (HDAC4.com 2024).

Evidence & Benchmarks

• M344 exhibits an IC50 of 100 nM for HDAC inhibition in biochemical assays (APExBIO M344).
• It induces G0/G1 cell cycle arrest and caspase activation in neuroblastoma cells (Brumfield et al. 2025, https://doi.org/10.3390/ijms26178494).
• At 1–7 day exposures, GI50 values for MCF-7, D341 MED, and CH-LA 90 cell lines range from 0.63–0.65 μM (APExBIO M344, https://www.apexbt.com/m344.html).
• M344 synergistically enhances response to radiation in human squamous carcinoma (SCC-35 and SQ-20B) models (GAP-26.com 2024).
• In HIV-1 latency models, M344 increases LTR-driven gene expression through NF-κB activation (HDAC4.com 2024).
• M344 demonstrates solubility of ≥14.75 mg/mL in DMSO and ≥12.88 mg/mL in ethanol at 37°C with ultrasonic agitation (APExBIO M344, https://www.apexbt.com/m344.html).
• In vivo, metronomic dosing of M344 suppresses tumor growth and extends survival in neuroblastoma mouse models (Brumfield et al. 2025, https://doi.org/10.3390/ijms26178494).
• Relative to vorinostat (SAHA), M344 displays superior cytostatic and migration-inhibitory effects in neuroblastoma (Brumfield et al. 2025, https://doi.org/10.3390/ijms26178494).

This article extends the discussion from GAP-26.com by detailing new in vivo efficacy data and clarifies clinical translation potential beyond prior in vitro benchmarks. It also updates the workflows described in HDAC4.com with specific solubility and storage protocols for higher reproducibility.

Applications, Limits & Misconceptions

M344 is validated for:

• Epigenetic modulation in cancer cell lines (e.g., neuroblastoma, breast cancer, medulloblastoma).
• Induction of cell differentiation and apoptosis for functional genomics assays.
• Enhancement of radiation therapy response in squamous carcinoma models.
• Activation of latent HIV-1 gene expression for anti-latency research.
• Comparative studies with other HDAC inhibitors (e.g., SAHA/vorinostat).

Common Pitfalls or Misconceptions

• M344 is insoluble in water; use DMSO or ethanol with ultrasonic agitation at 37°C for best results (APExBIO M344).
• Not all HDAC isoforms are equally inhibited; activity is most robust against class I/II HDACs (Brumfield et al. 2025).
• Solutions should not be stored long-term; prepare fresh aliquots for each experiment to maintain activity (APExBIO M344).
• Toxicity increases above 10 μM; for survival and differentiation studies, do not exceed this threshold (Brumfield et al. 2025).
• M344 is less favorable for brain slice cultures compared to SAHA; select alternative HDACis for certain ex vivo or CNS models (Brumfield et al. 2025).

Workflow Integration & Parameters

M344 is supplied as a solid by APExBIO and should be stored at -20°C. For in vitro studies, dissolve at ≥14.75 mg/mL in DMSO or ≥12.88 mg/mL in ethanol, using ultrasonic agitation and warming at 37°C. Typical experimental concentrations are 1–100 μM, with treatment durations from 1 to 7 days. For proliferation or apoptosis assays, do not exceed 10 μM unless assessing cytotoxicity. Solutions should be prepared fresh for each use. Avoid prolonged storage of working solutions to prevent degradation. For mechanistic studies, pair M344 with immunoblotting for histone acetylation and flow cytometry for cell cycle/apoptosis endpoints (APExBIO M344). Full protocols and comparative guidance are discussed in detail in Z-DQMD-FMK.com, which this article updates by offering explicit storage/solubility details and referencing new in vivo combination regimens.

Conclusion & Outlook

M344 stands out as a potent and versatile HDAC inhibitor for cancer and HIV-1 latency research. Its nanomolar potency, robust activity in neuroblastoma and other models, and defined mechanisms provide a foundation for translational applications. Future studies may expand its use in combinatorial regimens and refine its clinical relevance. For detailed lot-specific information and ordering, consult the APExBIO M344 product page.